Author:
Chicheportiche Alexandre,Sason Moshe,Zidan Mahmoud,Godefroy Jeremy,Krausz Yodphat,Gross David J.,Grozinsky-Glasberg Simona,Ben-Haim Simona
Publisher
Society of Nuclear Medicine
Subject
Radiology, Nuclear Medicine and imaging
Reference26 articles.
1. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors
2. 177Lu-dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial;Strosberg;Lancet Oncol.,2021
3. Treatment With the Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate: Toxicity, Efficacy, and Survival
4. FDA approves lutetium Lu 177 dotatate for treatment of GEP-NETS. U.S. Food and Drug Administration website. https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm594105.htm. Revised January 26, 2018. Accessed July 10, 2023.
5. Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: a simulation study;Del Prete;Eur J Nucl Med Mol Imaging.,2017
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献